Biomedical subjects

M Kanliöz

Publications and source records attributed to M Kanliöz.

3 recordsLinked to original sources

PubMed2002

Menstrual cycle and hormone receptor status in breast cancer patients.

Hormone receptors in normal breast tissue were reported to be under the influence of cyclic variations of serum hormones during the menstrual cycle. The current study aimed to demonstrate a similar relationship between the phase of the menstrual cycle and hormone receptor status in operable, premenopausal patients with breast cancer. Patients were prospectively categorized according to the first day of last menstrual period into clinically defined follicular/luteal, perimenstrual/mid-cycle and unopposed estrogen/rest of the cycle phases and hormonally defined follicular/luteal phases. Serum follicle-stimulating hormone, luteinizing hormone, estrogen and progesterone levels were determined on the day of the operation. Estrogen and progesterone receptors in the tissues were detected by immunohistochemistry. Eighty-eight consecutive premenopausal patients with breast cancer were included in the study. Estrogen and progesterone receptors were positive in 57 (64.8%) and 40 (70.2%) patients respectively. Forty-nine patients were in follicular, and 39 patients in luteal phases according to serum hormone levels. Estrogen receptor positivity was significantly higher in hormonally defined follicular phase (p=0.025) and also had a tendency to be higher in perimenstrual phase (p=0.048). In contrast, progesterone receptor status was found to be independent of the phases of the menstrual cycle. As a conclusion, hormone receptor status might change during different phases of the menstrual cycle due to a possible effect of the circulating hormones and if it is found as negative, should he re-evaluated concerning the phase of the menstrual cycle in which the operation was performed.

Adult↗

PubMed2002

Comparison of prognostic scoring system to tumor node metastases 1992 and 1997 staging systems in gastric cancer patients.

Tumor node metastases staging systems have been widely utilized to predict the prognosis of gastric cancer patients. The current study aimed to compare a prognostic scoring system to tumor node metastases 1992 and 1997 staging systems in predicting the outcome of resectable gastric cancer patients. Patients treated between 1996-1998 were retrospectively evaluated. Tumor depth in the gastric wall, anatomical location and number of metastatic lymph nodes, metastatic to retrieved lymph node ratio, extent of surgical resection, tumor location, type of lymph node dissection, macroscopic appearence and histologic type of tumor were recorded and patients were divided into groups I-III due to their scores. Patients were also staged according to both tumor node metastases systems. Survival data was analyzed by Kaplan-Meier method. For the comparison of power of the three systems in predicting survival, log-rank and Cox regression analysis were respectively used for univariate and multivariate analysis. 163 resectable gastric cancer patients were evaluated. Median follow-up and survival times were 26 and 23 months respectively. Overall 5-year survival was 37.6%. The number of patients in prognostic scoring groups I, II and III was 44, 109 and 10, respectively. According to tumor node metastases 1992 system, 13, 43, 101 and 6 patients were in stages I, II, III and IV while there were 13, 38, 78 and 34 patients in respective stages in tumor node metastases 1997 system. Although tumor node metastases 1992 (p=0.0088), 1997 (p=0.0029) and prognostic scoring systems (p=0.0006) significantly predicted the survival of patients in univariate analysis, prognostic scoring system was found to be superior compared to other two systems in multivariate analysis (p=0.0002). Prognostic scoring system is a practical, reliable and reproducible method that could be used as an adjunct to tumor node metastases systems in predicting survival of resectable gastric cancer patients.

Adult↗

PubMedDate not supplied

Primary gastrointestinal tract lymphomas.

AIM: To evaluate the prognostic factors and treatment modalities affecting survival in patients with primary gastrointestinal tract lymphoma. MATERIAL AND METHODS: Gastrointestinal tract lymphoma patients were retrospectively studied. Age and sex of patients, location and histopathological grade of tumour, stage of disease, extent of surgical resection and chemotherapy were evaluated as prognostic factors. Effects of clinicopathological and treatment associated factors on disease-free and overall survival were calculated in univariate and multivariate analyses. RESULTS: On univariate analysis, disease stage (p = 0.002), extent of surgical resection (p = 0.003) and chemotherapy (p = 0.001) were found to be significantly affecting overall survival and none of the studied factors were found to be related with disease-free survival. Multivariate analysis revealed that grade of the tumour (p = 0.042) and chemotherapy (p = 0.028) significantly affected disease-free survival and disease stage (p = 0.013) and chemotherapy (p = 0.0003) were independent prognostic factors for overall survival. In addition, surgery and chemotherapy in combination, significantly increased overall survival compared to surgery or chemotherapy only. CONCLUSION: Early stage patients have a better survival and it could be prolonged if surgery with no residual disease is performed; adjuvant chemotherapy provides an additional benefit.

Adolescent↗